Sanofi, Regeneron Advised of 'Neurocognitive Adverse Events' in New Drug

The U.S. Food and Drug Administration has become aware of cognitive adverse events related to a closely watched group of experimental cholesterol drugs being developed by large drug firms, Sanofi SA said in a regulatory filing Friday.

The FDA has asked Sanofi and Regeneron Pharmaceuticals Inc., which are co-developing one of the drugs, known as PCSK9 inhibitors, to assess the potential for their drug to cause neurocognitive adverse...